Back to Search
Start Over
New application of an old drug proparacaine in treating epilepsy via liposomal hydrogel formulation.
- Source :
-
Pharmacological Research . Jul2021, Vol. 169, pN.PAG-N.PAG. 1p. - Publication Year :
- 2021
-
Abstract
- Proparacaine (PPC) is a previously discovered topical anesthetic for ophthalmic optometry and surgery by blocking the central Nav1.3. In this study, we found that proparacaine hydrochloride (PPC-HCl) exerted an acute robust antiepileptic effect in pilocarpine-induced epilepsy mice. More importantly, chronic treatment with PPC-HCl totally terminated spontaneous recurrent seizure occurrence without significant toxicity. Chronic treatment with PPC-HCl did not cause obvious cytotoxicity, neuropsychiatric adverse effects, hepatotoxicity, cardiotoxicity, and even genotoxicity that evaluated by whole genome-scale transcriptomic analyses. Only when in a high dose (50 mg/kg), the QRS interval measured by electrocardiography was slightly prolonged, which was similar to the impact of levetiracetam. Nevertheless, to overcome this potential issue, we adopt a liposome encapsulation strategy that could alleviate cardiotoxicity and prepared a type of hydrogel containing PPC-HCl for sustained release. Implantation of thermosensitive chitosan-based hydrogel containing liposomal PPC-HCl into the subcutaneous tissue exerted immediate and long-lasting remission from spontaneous recurrent seizure in epileptic mice without affecting QRS interval. Therefore, this new liposomal hydrogel formulation of proparacaine could be developed as a transdermal patch for treating epilepsy, avoiding the severe toxicity after chronic treatment with current antiepileptic drugs in clinic. [Display omitted] • Proparacaine, a local anesthetic drug, exerts rapid, robust, and persistent antiepileptic property. • No obvious cytotoxicity, neuropsychiatric adverse effects, genotoxicity, and cardiotoxicity after proparacaine treatment. • The antiepileptic effect of newly prepared proparacaine liposome hydrogel is remarkable without cardiotoxicity. • Proparacaine could be developed as a transdermal patch for curing epilepsy, avoiding the severe toxicity in clinic. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10436618
- Volume :
- 169
- Database :
- Academic Search Index
- Journal :
- Pharmacological Research
- Publication Type :
- Academic Journal
- Accession number :
- 150931555
- Full Text :
- https://doi.org/10.1016/j.phrs.2021.105636